Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker VIR · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination… NCT05356741 · Locally Advanced or Metastatic HER2-Expressing Cancers VIR-5818, pembrolizumab | VIR Vir Biotechnology, Inc. | Phase 1/2 | Recruiting | 645 | Apr 2028 | Registry ↗ |
| Nov 3, 2026 | A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection NCT06903338 · Viral Hepatitis Tobevibart, Elebsiran | VIR Vir Biotechnology, Inc. | Phase 3 | Active, not recruiting | 124 | Sep 30, 2026 | Registry ↗ |
| Oct 16, 2026 | A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218 NCT05844228 · Renal Impairment VIR-2218 | VIR Vir Biotechnology, Inc. | Phase 1 | Completed | 28 | Mar 1, 2025 | Registry ↗ |
| Sep 9, 2026 | Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 NCT05484206 · Hepatic Impairment, Cirrhosis VIR-2218, VIR-3434 | VIR Vir Biotechnology, Inc. | Phase 1 | Completed | 88 | Dec 9, 2025 | Registry ↗ |
| Jul 13, 2026 | A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virological… NCT07128550 · Viral Hepatitis Tobevibart, Elebsiran | VIR Vir Biotechnology, Inc. | Phase 3 | Active, not recruiting | 150 | Dec 2026 | Registry ↗ |
| Jun 26, 2026 | SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection. NCT05461170 · Hepatitis D, Chronic VIR-2218, VIR-3434 | VIR Vir Biotechnology, Inc. | Phase 2 | Active, not recruiting | 95 | Nov 2031 | Registry ↗ |
| Apr 23, 2026 | Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection NCT04856085 · Hepatitis B, Chronic VIR-2218, VIR-3434 | VIR Vir Biotechnology, Inc. | Phase 2 | Completed | 244 | Mar 16, 2026 | Registry ↗ |
| Apr 16, 2026 | Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis… NCT04412863 · Chronic Hepatitis B VIR-2218, pegylated interferon-alfa 2a | VIR Vir Biotechnology, Inc. | Phase 2 | Completed | 84 | Mar 25, 2024 | Registry ↗ |
| Apr 13, 2026 | Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Local… NCT06960395 · Solid Tumor Malignancies, EGFR Positive Solid Tumors VIR-5525, Pembrolizumab | VIR Vir Biotechnology, Inc. | Phase 1 | Recruiting | 450 | Aug 2029 | Registry ↗ |
| Feb 9, 2026 | A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection NCT05612581 · Hepatitis B, Chronic VIR-3434, VIR-2218 | VIR Vir Biotechnology, Inc. | Phase 1/2 | Completed | 33 | Oct 15, 2024 | Registry ↗ |
| Jan 16, 2026 | A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection NCT07142811 · Viral Hepatitis Tobevibart, Elebsiran | VIR Vir Biotechnology, Inc. | Phase 2 | Active, not recruiting | 100 | Nov 2026 | Registry ↗ |
| Oct 8, 2024 | Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection NCT04423393 · Chronic Hepatitis B VIR-3434, Placebo | VIR Vir Biotechnology, Inc. | Phase 1 | Completed | 113 | Oct 24, 2022 | Registry ↗ |
| Sep 19, 2024 | A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due t… NCT05567783 · Influenza A VIR-2482 (450 mg), VIR-2482 (1200 mg) | VIR Vir Biotechnology, Inc. | Phase 2 | Terminated | 2,977 | May 5, 2023 | Registry ↗ |
| Sep 19, 2024 | Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (C… NCT05280717 · Covid19 sotrovimab, sotrovimab | VIR Vir Biotechnology, Inc. | Phase 1 | Terminated | 316 | Apr 5, 2023 | Registry ↗ |
| Jun 7, 2024 | A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or… NCT04988152 · Covid19 sotrovimab, Placebo to Biologic | VIR Vir Biotechnology, Inc. | Phase 1 | Completed | 48 | Sep 2, 2021 | Registry ↗ |
| Mar 7, 2024 | Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19. NCT04913675 · Covid19 sotrovimab, sotrovimab | VIR Vir Biotechnology, Inc. | Phase 3 | Terminated | 1,065 | Jul 19, 2022 | Registry ↗ |
| May 3, 2023 | Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalize… NCT04779879 · Covid19 Sotrovimab (Gen1), Sotrovimab (Gen2) | VIR Vir Biotechnology, Inc. | Phase 2 | Completed | 354 | Aug 20, 2021 | Registry ↗ |
| Feb 27, 2023 | VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Vol… NCT04725877 · HIV I Infection VIR-1111, Placebo | VIR Vir Biotechnology, Inc. | Phase 1 | Completed | 27 | Dec 5, 2022 | Registry ↗ |
| Nov 10, 2022 | Sotrovimab Expanded Access Treatment Protocol (COVID-19) NCT05235347 · Covid19 Sotrovimab | VIR Vir Biotechnology, Inc. | — | No longer available | — | — | Registry ↗ |
| Nov 7, 2022 | VIR-7831 for the Early Treatment of COVID-19 in Outpatients NCT04545060 · Covid19 VIR-7831 (sotrovimab), Placebo | VIR Vir Biotechnology, Inc. | Phase 2/3 | Completed | 1,057 | Apr 8, 2021 | Registry ↗ |
| Jun 9, 2022 | Study of VIR-2482 in Healthy Volunteers NCT04033406 · Influenza A VIR-2482, Placebo | VIR Vir Biotechnology, Inc. | Phase 1 | Completed | 100 | Nov 1, 2021 | Registry ↗ |
| Dec 13, 2021 | Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B NCT03672188 · Chronic Hepatitis B VIR-2218, Placebo | VIR Vir Biotechnology, Inc. | Phase 1/2 | Completed | 82 | Sep 3, 2020 | Registry ↗ |
22 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:33 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances